-
Uncategorized2 months ago
Novo and Lilly battle over GLP-1 claims only a head-to-head trial can answer
A day after Eli Lilly gained FDA approval for its obesity pill Foundayo, Novo Nordisk is fighting back with an analysis that it says shows the...
-
Uncategorized2 months ago
UK signs off on US pharma deal, ensuring tariff reprieve as Britain aims to reattract investments
The U.K.’s end of the deal requires it to spend more on drugs through its National Health Service, which it is implementing through a higher cost-effectiveness...
-
Uncategorized2 months ago
Drug substance maker raises prices due to energy crisis; SpectronRX gets $85M
Plus, news about Scinai Immunotherapeutics and Cardinal Health: 📈 Drug ingredients company raises prices: As the war in the Middle East continues, BASF Pharma Solutions said...
-
Uncategorized2 months ago
Trump is preparing 100% tariffs on some drugmakers, documents show
President Donald Trump is reportedly set to implement 100% pharmaceutical tariffs as soon as Thursday, but according to a draft seen by Endpoints News, it appears...
-
Uncategorized2 months agoSTAT+: Lilly’s obesity pill enters the oral GLP-1 game, Novo responds
The FDA yesterday approved Eli Lilly’s weight loss pill, orforglipron. The agency is also facing renewed scrutiny over transparency gaps related to advisory committee conflicts, and its...
-
Uncategorized2 months agoGlobal initiative to tackle gaps in ALS/MND drug discovery
A global initiative has launched to close the gap in ALS/MND drug discovery. The ALS Therapy Development Institute (ALS TDI), LifeArc, and Axol Bioscience announced the launch of ‘Patient induced...
-
Uncategorized2 months agoCDC stops testing for rabies, pox viruses
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. A new Gallup poll found that...
-
Uncategorized2 months ago
Alto Neuroscience shelves schizophrenia cognitive impairment program after Phase 2 miss
Alto Neuroscience said its PDE4 inhibitor failed a mid-stage trial in schizophrenia-related cognitive impairment, prompting the biotech to drop plans to advance the program on its...
-
Uncategorized2 months agoSTAT+: ‘Takeover Tuesday’ saves biotech’s quarter
This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. In the nick...
-
Uncategorized2 months ago
Immunovant’s FcRn drug fails in a pair of Phase 3 trials in thyroid eye disease
Immunovant’s batoclimab failed in two late-stage trials in thyroid eye disease (TED). It already said it probably wasn’t going to advance the drug further in a...
Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins
STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
